Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Auxiliadora Gómez España"'
Autor:
María Victoria García-Ortiz, Pablo Cano-Ramírez, Marta Toledano-Fonseca, María Teresa Cano, Elizabeth Inga-Saavedra, Rosa María Rodríguez-Alonso, Silvia Guil-Luna, María Auxiliadora Gómez-España, Antonio Rodríguez-Ariza, Enrique Aranda
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-15 (2023)
Abstract Background Pancreatic cancer is the most lethal cancer with a dismal prognosis mainly due to diagnosis at advanced stage and ineffective treatments. CA19-9 levels and computed tomography (CT) imaging are the main standard criteria for evalua
Externí odkaz:
https://doaj.org/article/e442b4ca5a724ef38f833fa78d27c3c6
Autor:
Ramón Salazar, Jaume Capdevila, Jose Luis Manzano, Carles Pericay, Mercedes Martínez-Villacampa, Carlos López, Ferrán Losa, María José Safont, Auxiliadora Gómez-España, Vicente Alonso-Orduña, Pilar Escudero, Javier Gallego, Beatriz García-Paredes, Amalia Palacios, Sebastiano Biondo, Cristina Grávalos, Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Preoperative chemoradiotherapy with capecitabine is considered as a standard of care for locally advanced rectal cancer. The “Tratamiento de Tumores Digestivos” group (TTD) previously reported in a randomized Ph II study that
Externí odkaz:
https://doaj.org/article/a4aa7e2c60b44e39af5cbf4a269301f7
Autor:
Enrique Aranda, Barbara Manzanares-Martin, Arancha Cebrián Aranda, Laura del Puerto-Nevado, Rafael González, Sonia Solanes, Maria Auxiliadora Gómez-España, Jesús García-Foncillas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Aim Cetuximab is a standard-of-care treatment for KRAS wild-type metastatic colorectal cancer (mCRC), but it may also be effective in a subgroup of KRAS mutant patients by its immunomodulatory activity. Here, we explore if KIR (killer cell immunoglob
Externí odkaz:
https://doaj.org/article/1734a5cc131b4a0fb898b7c944efcb18
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rafael Mena‐Osuna, Ana Mantrana, Silvia Guil‐Luna, María Teresa Sánchez‐Montero, Carmen Navarrete‐Sirvent, Teresa Morales‐Ruiz, Aurora Rivas‐Crespo, Marta Toledano‐Fonseca, María Victoria García‐Ortíz, Gema García‐Jurado, María Auxiliadora Gómez‐España, Rafael González‐Fernández, Carlos Villar, Francisco Javier Medina‐Fernández, José Manuel Villalba, Enrique Aranda, Antonio Rodríguez‐Ariza
Publikováno v:
The Journal of Pathology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1686907d5699fa9fcb9061b3da2810a1
https://doi.org/10.1002/path.6080
https://doi.org/10.1002/path.6080
Autor:
Antonieta Salud, Manuel Valladares-Ayerbes, Javier Sastre, Elena Asensio, Luis Robles, Eduardo Díaz-Rubio, Fernando Rivera, Enrique Aranda, Albert Abad, Auxiliadora Gómez-España, Vicente Alonso-Orduña, Alfredo Carrato, Clara Montagut, Maria Jose Safont, Cristina García González, Manuel Benavides, Encarnación González-Flores, Pilar García-Alfonso, Jose María Vieitez
Publikováno v:
European Journal of Surgical Oncology. 48:1123-1132
Retrospective studies and meta-analyses suggest that upfront primary tumour resection (UPTR) confers a survival benefit in patients with asymptomatic unresectable metastatic colorectal cancer (mCRC) undergoing chemotherapy, however a consensus of its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecbf9e4a4e449540292ffcb4f5803e5e
https://doi.org/10.1016/j.ejso.2021.11.122
https://doi.org/10.1016/j.ejso.2021.11.122
Autor:
M. José Ortiz-Morales, Marta Toledano-Fonseca, Rafael Mena-Osuna, M. Teresa Cano, Auxiliadora Gómez-España, Juan R. De la Haba-Rodríguez, Antonio Rodríguez-Ariza, Enrique Aranda
Publikováno v:
Cancers; Volume 14; Issue 13; Pages: 3054
Cancers 14(13), 3054 (2022)
Helvia. Repositorio Institucional de la Universidad de Córdoba
instname
Cancers 14(13), 3054 (2022)
Helvia. Repositorio Institucional de la Universidad de Córdoba
instname
The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some compone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfd44df1a0b0a08ec917351a7af78401
https://www.mdpi.com/2072-6694/14/13/3054/pdf?version=1655972800
https://www.mdpi.com/2072-6694/14/13/3054/pdf?version=1655972800
Autor:
Elena Élez, María Auxiliadora Gómez-España, Cristina Grávalos, Pilar García-Alfonso, María José Ortiz-Morales, Ferrán Losa, Inmaculada Alés Díaz, Begoña Graña, Marta Toledano-Fonseca, Manuel Valladares-Ayerbes, Eduardo Polo, Mercedes Salgado, Eva Martínez de Castro, María José Safont, Antonieta Salud, Ana Ruiz-Casado, Josep Tabernero, María del Carmen Riesco, Antonio Rodriguez-Ariza, Enrique Aranda
Publikováno v:
Br J Cancer
[Background] Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f48a8580d2d85d770659b388b474173
https://hdl.handle.net/10668/19521
https://hdl.handle.net/10668/19521
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.